COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Medicare & Medicaid Services updated its COVID-19 FAQs to address emerging questions regarding Medicare fee-for-service billing.
Six national organizations representing hospitals, including the AHA, urge the Centers for Medicare & Medicaid Services to delay the start of repayments associated with the Medicare Accelerated and Advance Payment Programs.
The Food and Drug Administration issued emergency use authorizations to Xiamen Biotime Biotechnology Co. and Access Bio Inc. for serology-based tests to detect SARS-CoV-2 antibodies indicating recent or prior infection.
The Centers for Medicare & Medicaid Services released an updated snapshot of the impact of COVID-19 on the Medicare population, which includes COVID-19 cases and hospitalizations through June 20 and the first data for American Indian/Alaskan Native Medicare beneficiaries.
The Food and Drug Administration reissued its emergency use authorization for the LabCorp COVID-19 RT-PCR Test to include authorized use for asymptomatic individuals and for pooled sample testing with up to five individual specimens.
The Food and Drug Administration updated its resource for labs performing authorized COVID-19 tests.
The Centers for Disease Control and Prevention recently posted updated considerations for ending isolation for adults with COVID-19, based on new evidence.
When ordering COVID-19 laboratory tests or collecting specimens, health care providers should collect certain patient demographic information and responses to certain questions needed for COVID-19 data reporting, according to updated guidance from the Centers for Disease Control and Prevention.
The Department of Health and Human Services (HHS) this week shared additional information on reporting requirements for recipients of provider relief funds authorized under the Coronavirus Aid, Relief, and Economic Security (CARES) Act and Paycheck Protection Program and Health Care Enhancement Act…
An estimated 2.8% of Indiana residents aged 12 or older randomly tested in late April had SARS-CoV-2 infection or antibodies, and 44% of those with active infections reported no symptoms, according to a July 21 report released by the Centers for Disease Control and Prevention.